rs2033962

Positions:

• chr2-157781929-A-C
• chr2-157781929-A-G
• chr2-157781929-A-T

Variant summary

Our verdict is Benign. Variant got -12 ACMG points: 0P and 12B. BP4_Strong BA1

The NM_001111067.4(ACVR1):​c.68-1329T>G variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.808 in 152,068 control chromosomes in the GnomAD database, including 49,785 homozygotes. In-silico tool predicts a benign outcome for this variant. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar.

• Frequency: Genomes: 𝑓 0.81 (49785 hom., cov: 31)
• Consequence: ACVR1 NM_001111067.4 intron
• Clinical Significance: Not reported in ClinVar
• Conservation: PhyloP100: -0.0200

Genes affected

ACVR1 (HGNC:171): (activin A receptor type 1) Activins are dimeric growth and differentiation factors which belong to the transforming growth factor-beta (TGF-beta) superfamily of structurally related signaling proteins. Activins signal through a heteromeric complex of receptor serine kinases which include at least two type I ( I and IB) and two type II (II and IIB) receptors. These receptors are all transmembrane proteins, composed of a ligand-binding extracellular domain with cysteine-rich region, a transmembrane domain, and a cytoplasmic domain with predicted serine/threonine specificity. Type I receptors are essential for signaling; and type II receptors are required for binding ligands and for expression of type I receptors. Type I and II receptors form a stable complex after ligand binding, resulting in phosphorylation of type I receptors by type II receptors. This gene encodes activin A type I receptor which signals a particular transcriptional response in concert with activin type II receptors. Mutations in this gene are associated with fibrodysplasia ossificans progressive. [provided by RefSeq, Jul 2008]

ACMG classification

Verdict is Benign. Variant got -12 ACMG points.

• BP4: Computational evidence support a benign effect (BayesDel_noAF=-0.82).
• BA1: GnomAd4 highest subpopulation (EAS) allele frequency at 95% confidence interval = 0.911 is higher than 0.05.

Transcripts

RefSeq

Gene	Transcript	HGVSc	HGVSp	Effect	#exon/exons	MANE	UniProt
ACVR1	NM_001111067.4	c.68-1329T>G		intron_variant		ENST00000434821.7

Ensembl

Gene	Transcript	HGVSc	HGVSp	Effect	#exon/exons	TSL	MANE	Appris	UniProt
ACVR1	ENST00000434821.7	c.68-1329T>G		intron_variant		1	NM_001111067.4	P4

Frequencies

GnomAD3 genomes AF: 0.808 AC: 122736 AN: 151950 Hom.: 49738 Cov.: 31

Gnomad AFR AF: 0.735

Gnomad AMI AF: 0.781

Gnomad AMR AF: 0.844

Gnomad ASJ AF: 0.857

Gnomad EAS AF: 0.933

Gnomad SAS AF: 0.861

Gnomad FIN AF: 0.851

Gnomad MID AF: 0.842

Gnomad NFE AF: 0.821

Gnomad OTH AF: 0.812

We have no GnomAD4 exomes data on this position. Probably position not covered by the project.

GnomAD4 genome AF: 0.808 AC: 122843 AN: 152068 Hom.: 49785 Cov.: 31 AF XY: 0.811 AC XY: 60278 AN XY: 74334

Gnomad4 AFR AF: 0.735

Gnomad4 AMR AF: 0.845

Gnomad4 ASJ AF: 0.857

Gnomad4 EAS AF: 0.933

Gnomad4 SAS AF: 0.861

Gnomad4 FIN AF: 0.851

Gnomad4 NFE AF: 0.821

Gnomad4 OTH AF: 0.814

Alfa AF: 0.801 Hom.: 4620

Bravo AF: 0.799

Asia WGS AF: 0.897 AC: 3115 AN: 3476

ClinVar

Not reported in ClinVar

Computational scores

Source: dbNSFP v4.3

Name	Calibrated prediction	Score	Prediction
BayesDel_noAF	Benign	-0.82
CADD	Benign	5.9
DANN	Benign	0.63

Splicing

Name	Calibrated prediction	Score	Prediction
SpliceAI score (max)		0.0		Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Other links and lift over

dbSNP: rs2033962; hg19: chr2-158638441;